Combating hepatocellular carcinoma with an integrated approach

Chinese Medical Journal

Volumn 112, Issue 1, 1999, Pages 80-83

  Ho, S ^a   Johnson, P J ^a   Leung, W T ^a   Lau, W Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hepatocellular carcinoma; Integrated approach

Indexed keywords

YTTRIUM 90;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHRONIC LIVER DISEASE; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; RADIATION DOSE; TREATMENT PLANNING;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; DRUGS, CHINESE HERBAL; HUMANS; IODINE RADIOISOTOPES; LIVER NEOPLASMS; MICROSPHERES; RADIOTHERAPY, ADJUVANT; YTTRIUM RADIOISOTOPES;

EID: 0032918961     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985;56:918-928.
2. Shiu W, Dewar G, Leung N, et al. Hepatocellular carcinoma in Hong Kong: clinical study on 340 cases. Oncology 1990;47:241-245.
3. Di Bisceglie AM, Hoofnagle JH. Elevations in serum alpha-feto-protein levels in patients with chronic hepatitis B. Cancer 1989; 64:2117-2120.
4. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-feto-protein levels. Cancer 1989;64:1700-1707.
5. Alpert E, Feller ER. Alpha-fetoprotein (AFP) in benign liver disease: evidence that normal liver regeneration does not induce AFP synthesis. Gastroenterology 1978;74:856-858.
6. Moore D Jr. , Pazdur R. Systemic therapies for unresectable primary hepatic tumours. J Surg Oncol 1993;3(Suppl): 112-114.
7. Nakamura H, Mitani T, Murakami T, et al. Five year survival after transcathether chemoembolization for hepatocellular carcinoma. Cancer Chemother Pharmacol 1994;33(Suppl):S89-S92.
8. Groupe, De' Etude, Et De. Traitement, Du Carcinoma Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256-1261.
9. Friedman MA. Primary hepatocellular cancer: present results and future prospects. Int J Radiat Oncol Biol Phys 1983;9:1841-1850.
10. Ingold JA, Reed GB, Kaplan HS, et al. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 1965;93:200-208.
11. Sasaki Y, Imaoka S, Fujita M, et al. Regional therapy in the management of intrahepatic recurrence after surgery for hepatoma. Ann Surg 1987;206:40-47.
12. Nagasue N, Yukaya H, Ogawa Y, et al. Second hepatic resection for recurrent hepatocellular carcinoma. Br J Surg 1986;73: 434-438.
13. Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alphafetoprotein. N Eng J Med 1993;328:1802-1806.
14. Burditt LJ, Johnson MM, Johnson PJ, et al. Detection of hepatocellular carcinoma-specific alphafetoprotein by isoelectric focusing. Cancer 1994;74:25-29
15. Ho S, Cheng P, Yuen J, et al. Isoelectric focusing of alphafetoprotein in patients with hepatocellular carcinoma: frequency of specific banding patterns at non-diagnostic serum levels. Br J Cancer 1996;73:985-988.
16. Johnson PJ, Leung N, Cheng P, et al. 'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease. Br J Cancer 1997;75:236-240.
17. Herba MJ, Illes FF, Thirlwell MP, et al. Hepatic malignancies: Improved treatment with intraarterial yttrium-90. Radiology 1988;169:311-314.
18. Fox RA, Klemp PFB, Egan G, et al. Dose distribution following selective internal radiation therapy. Int J Radiat Oncol Biol Phys 1991;21:463-467.
19. Shepherd FA, Rotsein LE, Houle S, et al. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of hepatocellular carcinoma. Cancer 1992;70:2250-2254.
20. Lau WY, Leung TWT, Ho S, et al. Treatment of inoperable hepatocellular carcinoma with yttrium-90 microspheres. A phase I & II study. Br J Cancer 1994;70:994-999.
21. Ho S, Lau WY, Leung WT, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic rumours. Eur J Nucl Med 1996;23:947-952.
22. Ho S, Lau WY, Leung TWT, et al. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 1997; 24:293-297.
23. 131 Iodine-Lipiodol in inoperable hepatocellular carcinoma. J Nucl Med 1994;35:1313-1318.